HKSE - Delayed Quote HKD

BeOne Medicines Ltd. (6160.HK)

160.000

-2.400

(-1.48%)

At close: 4:08:30 PM GMT+8

BeOne Medicines And 2 Stocks That May Be Undervalued By The Market

The United States market has shown positive momentum, rising 1.6% over the last week and 12% over the past year, with earnings projected to grow by 14% annually in the coming years. In such a climate, identifying undervalued stocks like BeOne Medicines can offer potential opportunities for investors seeking value amidst broader market gains.

Simply Wall St. 23 hours ago

BEIGF

ONC

TFC
Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple

Cancer stock BeiGene renamed itself as BeOne. Shares have gained 40% year to date, outperforming the S&P 500.

Investor's Business Daily 4 days ago

BEIGF

ONC
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025

SAN CARLOS, Calif., June 02, 2025--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including

Business Wire 8 days ago

BEIGF

ONC
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025

SAN CARLOS, Calif., May 31, 2025--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO)

Business Wire 9 days ago

BEIGF

ONC
Sector Update: Health Care Stocks Rise Premarket Tuesday

Health care stocks were edging higher premarket Tuesday as the Health Care Select Sector SPDR Fund (

PREMIUM
MT Newswires 13 days ago

ONC

RCKTW
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology

SAN CARLOS, Calif. & BASEL, Switzerland, May 27, 2025--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company formerly known as BeiGene, Ltd., today announced its new name and redomiciliation to Switzerland are officially in effect, marking a significant milestone in the Company’s evolution.

Business Wire 13 days ago

BEIGF

ONC
BeiGene Says EU Panel Recommends Tevimbra as Treatment for Nasopharyngeal Cancer

BeiGene (ONC) said Tuesday that the European Medicines Agency's Committee for Medicinal Products for

PREMIUM
MT Newswires 14 days ago

ONC
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer

SAN CARLOS, Calif., May 27, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with recurrent, not amenable to curative surgery or

Business Wire 14 days ago

BEIGF

ONC
Exploring US High Growth Tech Stocks In May 2025

Over the last 7 days, the United States market has dropped 1.1%, yet it remains up by 9.1% over the past year with earnings forecasted to grow by 14% annually. In this context, identifying high growth tech stocks that can capitalize on these positive earnings projections is crucial for investors seeking opportunities in a dynamic and evolving sector.

Simply Wall St. 18 days ago

CYBR

SPRY

BEIGF
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors

SAN CARLOS, Calif., May 22, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share 23 abstracts featuring new data across its hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, May 30 – June 3, 2025. With two abstracts selected for rapid oral presentation, these data reflect the Company’s vision to address cancer acr

Business Wire 19 days ago

BEIGF

ONC
BeiGene (NasdaqGS:ONC) Reveals Promising Phase 1 Trial Results Across Multiple Cancer Studies

BeiGene (NasdaqGS:ONC) recently announced comprehensive analyses from clinical trials at EHA2025, focusing on hematological malignancies, reflecting its commitment to advancing treatment options. However, the company’s share price declined by 2.46% over the last quarter. Despite the unveiling of promising clinical data and revenue growth, these developments seem to have countered broader market trends, where major indices like the S&P 500 and Nasdaq Composite showed gains. BeiGene's improved...

Simply Wall St. 25 days ago

BEIGF

ONC
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation

SAN CARLOS, Calif., May 14, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUK

Business Wire 26 days ago

BEIGF

ONC
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

SAN CARLOS, Calif., May 13, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will participate in the RBC Capital Markets Global Healthcare Conference on May 20, 2025, with a fireside chat at 10 a.m. EDT.

Business Wire 28 days ago

BEIGF

ONC
BeiGene First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

BeiGene ( NASDAQ:ONC ) First Quarter 2025 Results Key Financial Results Revenue: US$1.12b (up 49% from 1Q 2024). Net...

Simply Wall St. 29 days ago

BEIGF

ONC
Earnings Beat: BeiGene, Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Last week, you might have seen that BeiGene, Ltd. ( NASDAQ:ONC ) released its first-quarter result to the market. The...

Simply Wall St. 30 days ago

BEIGF

ONC
BeiGene, Ltd. (ONC): Among Billionaire Lei Zhang’s Stock Picks with Huge Upside Potential

We recently published a list of Billionaire Lei Zhang’s 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where BeiGene, Ltd. (NASDAQ:ONC) stands against other billionaire Lei Zhang’s stock picks with huge upside potential. Lei Zhang and Hillhouse Capital: Quiet Power in Asian Investing Lei Zhang, […]

Insider Monkey last month

ONC
BeiGene Ltd (ONC) Q1 2025 Earnings Call Highlights: Achieving Profitability and Expanding ...

BeiGene Ltd (ONC) marks a milestone with its first GAAP profitability, driven by a 49% revenue increase and strong market performance of Brukinsa.

GuruFocus.com last month

ONC
Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics

The headline numbers for BeiGene (ONC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks last month

ONC
BeiGene Announces First Quarter 2025 Financial Results and Business Updates

SAN CARLOS, Calif., May 07, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025.

Business Wire last month

BEIGF

ONC
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

SAN CARLOS, Calif., April 29, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC’s (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding.

Business Wire last month

BEIGF

ONC

Performance Overview

Return	6160.HK	HANG SENG INDEX (^HSI)
YTD	+45.85%	+20.45%
1-Year	+67.80%	+31.56%
3-Year	+67.19%	+10.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BeOne Medicines Ltd. (6160.HK)

BeOne Medicines And 2 Stocks That May Be Undervalued By The Market

Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple

BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025

BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025

Sector Update: Health Care Stocks Rise Premarket Tuesday

BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology

BeiGene Says EU Panel Recommends Tevimbra as Treatment for Nasopharyngeal Cancer

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer

Exploring US High Growth Tech Stocks In May 2025

BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors

BeiGene (NasdaqGS:ONC) Reveals Promising Phase 1 Trial Results Across Multiple Cancer Studies

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

BeiGene First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Earnings Beat: BeiGene, Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

BeiGene, Ltd. (ONC): Among Billionaire Lei Zhang’s Stock Picks with Huge Upside Potential

BeiGene Ltd (ONC) Q1 2025 Earnings Call Highlights: Achieving Profitability and Expanding ...

Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics

BeiGene Announces First Quarter 2025 Financial Results and Business Updates

U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

Performance Overview